# Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

> **NCT00145613** · PHASE2 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 25 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Secondary AML
- Myelodysplastic Syndrome (MDS)
- Secondary MDS
- Chronic Myeloid Leukemia
- Juvenile Myelomonocytic Leukemia (JMML)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Lymphoma, Non-Hodgkin
- Hodgkin Disease

## Interventions

- **PROCEDURE:** Stem Cell Transplantation
- **DEVICE:** Miltenyi Biotec CliniMACS
- **DRUG:** Systemic chemotherapy and antibodies

## Key facts

- **NCT ID:** NCT00145613
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-07
- **Final completion:** 2009-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2009-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145613, "Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00145613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*